Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001192482-19-000256
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-15 16:06:04
Reporting Period:
2019-05-13
Accepted Time:
2019-05-15 16:06:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1588972 Recro Pharma Inc. REPH () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1236451 Geraldine Henwood C/o Recro Pharma, Inc.
490 Lapp Road
Malvern PA 19355
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-13 123,500 $2.47 342,947 No 4 M Direct
Common Stock Disposition 2019-05-13 123,500 $8.89 219,447 No 4 S Direct
Common Stock Disposition 2019-05-13 21,306 $8.89 198,141 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2019-05-13 123,500 $0.00 123,500 $2.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-12-17 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 50,000 Indirect By spouse
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.78 to $8.98, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 3 to this Form 4.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.84 to $8.92, inclusive.
  4. The shares subject to this option are fully vested and exercisable.